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Four cycles of rituximab plus CHOP (cyclophosphamide, doxorubicin,vincristine, and prednisone) chemotherapy is as effective as six cyclesin low-risk diffuse large B-cell lymphoma (DLBCL). Here we report a
post-hoc analysis of a prospective clinical trial in patients with human
immunodeficiency virus-associated DLBCL and high-grade lymphoma
treated with four to six cycles of EPOCH plus rituximab based on a
response-adapted treatment strategy. One hundred and six evaluable
patients with human immunodeficiency virus-associated DLBCL or high-
grade CD20+ non-Hodgkin lymphoma were randomized to receive ritux-
imab (375 mg/m2) given either concurrently prior to each infusional
EPOCH cycle, or sequentially (weekly for 6 weeks) following completion
of EPOCH. EPOCH consisted of a 96-hour intravenous infusion of etopo-
side, doxorubicin, and vincristine plus oral prednisone followed by an
intravenous bolus of cyclophosphamide every 21 days for four to six
cycles. Patients received two additional cycles of therapy after documen-
tation of a complete response by computed tomography after cycles 2 and
4. Sixty-four of 106 evaluable patients (60%; 95% confidence interval
[95% CI]: 50%-70%) in both treatment arms had a complete response.
The 2-year event-free survival rates were similar in the 24 patients with
complete response who received four or fewer cycles of EPOCH (78%;
95% CI: 55%-90%) due to having achieved a complete response after
two cycles, compared with those who received five or six cycles of
EPOCH (85%; 95% CI: 70%-93%) because a complete response was first
documented after cycle 4. A response-adapted strategy may permit a
shorter treatment duration without compromising therapeutic efficacy in
patients with human immunodeficiency virus-associated lymphoma
treated with EPOCH plus rituximab, which merits further evaluation in
additional prospective trials. Clinical Trials.gov identifier NCT00049036.
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ABSTRACT
Introduction
Six cycles of the anti-CD20 antibody rituximab (R) plus cyclophosphamide, dox-
orubicin, vincristine, and prednisone (CHOP) or CHOP-like chemotherapy are rec-
ommended by the European Society of Medical Oncology (ESMO) and National
Comprehensive Cancer Network (NCCN) practice guidelines for the treatment of
diffuse large B-cell lymphoma (DLBCL),1,2 a recommendation supported by popu-
lation-based data demonstrating similar outcomes after
six or eight cycles of therapy.3 Poeschel et al. reported the
non-inferiority of four cycles of R-CHOP (followed by 2
additional doses of rituximab) compared with six cycles of
R-CHOP in a randomized, phase III trial that included 588
immunocompetent patients with stage I-II DLBCL aged
18-60 years and an age-adjusted International Prognostic
Index score of 0, indicating that de-escalation of treatment
duration may be safely achieved without compromising
curability in an appropriately selected patient population.4
This provides a foundation for evaluation of therapeutic
de-escalation in other settings using other strategies.
Infusional administration of cytotoxic therapy has been
explored as a potential strategy in patients with poor-risk
lymphoma,5-8 including human immunodeficiency virus
(HIV)-associated lymphoma.9-13 Based upon these consid-
erations, the AIDS Malignancy Consortium conducted a
randomized, phase II trial of rituximab (375 mg/m2) given
either concurrently prior to each infusional EPOCH
chemotherapy cycle, or sequentially (weekly for 6 weeks)
following completion of all chemotherapy in patients
with HIV-associated DLBCL and high-grade lymphoma.14
EPOCH consisted of a 96-hour intravenous infusion of
etoposide, doxorubicin, and vincristine together with oral
prednisone followed by an intravenous bolus of
cyclophosphamide given every 21 days for four to six
cycles, with cyclophosphamide dose adjusted based on
pretreatment CD4 lymphocyte count, and subsequently
escalated or reduced based on the absence or presence of
treatment-associated cytopenias. The prespecified pri-
mary efficacy complete response endpoint of 75% was
met in the concurrently treated arm (73%, 95% confi-
dence interval [95% CI]: 58%-85%), but not in the arm
treated sequentially (55%, 95% CI: 41%-68%).14 Patients
were assessed by computed tomography (CT) of the
chest, abdomen, and pelvis after every two cycles of
EPOCH chemotherapy, and were treated for two cycles
beyond achieving a complete response for a minimum of
four and a maximum of six cycles of EPOCH. Two-year
time to progression rates were similar in the concurrently
treated arm (75%, 95% CI: 63%-88%) and the sequen-
tially treated arm (71%, 95% CI: 59%-84%). Inspired by
the successful de-escalation of R-CHOP therapy to four
cycles documented in a low-risk population with
DLBCL,4 here we report a post-hoc analysis of the out-
comes of patients with HIV-associated DLBCL and high-
grade lymphoma with higher risk features who achieved
a complete response when treated with four or fewer
cycles of therapy, based on having achieved a complete
response after two cycles of EPOCH.
Methods
Eligibility criteria and study conduct 
Details regarding eligibility criteria, treatment, and clinical out-
comes up to 2 years were previously reported.14 Briefly, eligibility
criteria included: (i) CD20+ B-cell non-Hodgkin lymphoma, includ-
ing DLBCL, Burkitt/Burkitt-like lymphoma, or other aggressive
lymphomas; (ii) HIV infection; (iii) stage II-IV disease (or stage I
disease with an elevated serum lactate dehydrogenase concentra-
tion); (iv) Eastern Cooperative Oncology Group performance sta-
tus of 0-2; (v) age 18 years or older;5 and (vi) adequate organ func-
tion, similarly to prior trials by the AIDS Malignancy
Consortium.15 The study was reviewed and approved by the
Cancer Evaluation Therapy Program of the National Cancer
Institute, and by the institutional review board at each participat-
ing institution. All patients provided written informed consent to
their inclusion in the analysis.
Response assessment and duration of therapy 
Response was defined by the 1999 International Response
Criteria for Non-Hodgkin Lymphoma (which utilizes anatomical
but not functional imaging).16 Response was evaluated after every
two cycles of EPOCH therapy with CT of the chest, abdomen,
and pelvis, and continued for two cycles beyond the achievement
of a complete response for a minimum of four and a maximum of
six cycles, including after completion of R-EPOCH in the concur-
rently treated arm, and after completion of EPOCH alone and fol-
lowing rituximab alone in the sequentially treated arm. All
patients had a bone marrow evaluation and lumbar puncture for
cerebrospinal fluid cytological examination at baseline. A repeat
bone marrow evaluation for confirmation of complete response
was required after completion of therapy if the baseline study
demonstrated lymphomatous marrow involvement. 2-Deoxy-2-
[fluorine-18]fluoro-D-glucose (FDG) positron emission tomogra-
phy (PET) scans were not required or consistently performed, and
when done were usually performed at the completion of therapy.
Event-free survival, time to progression, and overall survival were
estimated using the method of Kaplan and Meier. Event-free sur-
vival was defined as the time between registration and either
relapse or progression of lymphoma or death from any cause (thus
corresponding to progression-free survival in other reports17). Time
to progression was defined as time to progression or relapse of
lymphoma, with deaths from other causes censored. Patients
were followed for survival and recurrence up to 5 years after reg-
istration. We performed a post-hoc analysis to evaluate the out-
comes for patients who received only four cycles of therapy due
to achieving a complete response, as determined by CT scan, after
two cycles of therapy, compared with those who required five or
six cycles of therapy who achieved a complete response after four
cycles of therapy.
Results
Patients and response to therapy
A total of 106 evaluable patients were enrolled and ini-
tiated treatment at 20 sites of the AIDS Malignancy
Consortium between December 2002 and April 2006 and
are included in this analysis, as in the original, previously
described analysis.14 The disposition and outcomes of all
patients enrolled are shown in Figure 1. A complete
response was achieved by 64 of the 106 patients (60%,
95% CI: 50%-70%) who received any protocol therapy.
The null hypothesis of a complete response rate of 50%
was rejected in favor of the alternative of 75% for the con-
currently treated arm (P=0.005), but not for the sequential-
ly treated arm (P=0.394). Of the 64 patients who had a
complete response, 24 received four or fewer cycles of R-
EPOCH: 14/35 (40%) in the concurrently treated arm and
10/29 (34%) in the sequentially treated arm.
Characteristics of patients treated with four or fewer
versus five or six cycles of EPOCH therapy
Of 64 patients who achieved a complete response, 24
(38%, 95% CI: 26%-51%) received four or fewer cycles of
EPOCH based on their having achieved early complete
response after two cycles of therapy, whereas the remain-
ing 40 (63%, 95% CI: 50%-74%) received five or six
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cycles of therapy. The characteristics of the entire study
population, and patients who received four or fewer versus
five or six cycles are shown in Table 1. The characteristics
of the two groups were generally comparable to each
other, and to those of the entire study population, with
respect to gender, median age, baseline CD4 count, con-
current antiretroviral therapy, histology, and bone marrow
involvement at baseline. 
Information regarding histological subtype (germinal
center B-cell [GCB] subtype vs. non-GCB subtype) was
available for only 21 of the 64 patients who had a com-
plete response, with no significant difference in number
with non-GCB subtype for those who received four or
fewer cycles compared with those who received five or
six cycles (3/8 vs. 5/13 patients, P=1.000 Fisher exact test).
Treatment administered
A total of 322 cycles of EPOCH therapy were given to
J.A. Sparano et al.
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Figure 1. Consort diagram.
all 64 patients who achieved a complete response. Among
the 24 who received four or fewer cycles, five received
fewer than four cycles. The reasons for this were disease
progression after achieving a complete response (n=1),
physician’s decision (n=1), or other reasons (n=3). Among
the 40 who received five or six cycles of EPOCH, 36
received six cycles and four received five cycles due to
physicians’ decision (n=3) or unknown reasons (n=1).
Clinical outcomes by number of EPOCH treatment
cycles in complete responders
Outcome data for the 106 patients in the entire study
population, and the 64 patients who achieved complete
response are shown in Table 2 and Figure 2A-C. After a
median follow-up of 30 months (range, 0-67 months) for
all treated patients, 36 (34%, 95% CI: 25%-44%) died,
with relapsed lymphoma being the cause of death in eight
(8%, 95% CI: 3%-14%). After a median follow-up of 38.5
months (range, 1-66 months) in the 64 patients who
achieved a complete response, 11 (17%, 95% CI: 9%-
29%) died, five (8%, 95% CI: 3%-18%) with relapsed
lymphoma as the cause of death. Outcomes were similar
for those treated with four or fewer cycles compared with
those given five or six cycles with respect to rates of 2-
year event-free survival (78% vs. 85%), time to progres-
sion (91% vs. 87%), and overall survival (78% vs. 90%).
Discussion
In the absence of prospective comparative data in HIV-
associated lymphoma, six cycles of rituximab plus infu-
sional EPOCH is considered a preferred regimen for first-
line treatment of HIV-associated DLBCL, HHV8-positive
DLBCL, primary effusion lymphoma, and is also among
the preferred regimens for HIV-associated Burkitt lym-
phoma in the 2019 NCCN guidelines.2,18 These recom-
mendations were driven by the effectiveness of R-
EPOCH in individual phase II trials in HIV-associated
DLBCL and high-grade lymphoma,19,20 and results from a
large meta-analysis that demonstrated greater efficacy for
R-EPOCH as compared to R-CHOP in HIV-associated
lymphoma.21 On the other hand, a phase III trial compar-
ing R-CHOP with R-EPOCH in immunocompetent
patients with DLBCL found no difference in efficacy.17
Retrospective analysis showed that a high proliferation
rate was associated with better prognosis in HIV-associ-
ated lymphomas when treated with infusional R- EPOCH
but not with R-CHOP, suggesting that tumors with high
proliferation rates, such as high-grade lymphoma and a
subset of DLBCL may be those most likely to benefit
from infusional EPOCH chemotherapy.22 The findings
from our study suggest that patients with HIV-associated
lymphoma who achieve a complete response after two
cycles of EPOCH plus rituximab have excellent outcomes
when therapy is limited to four cycles, thereby sparing
toxicity associated with longer treatment durations.
Dunleavy et al. reported a phase II study including 33
patients with HIV-associated DLBCL who received three
to six cycles of dose-dense rituximab (SC-EPOCH-RR), of
whom 79% received three cycles of therapy based on a
risk-adapted approach of treating for one cycle beyond a
negative interim PET-CT after cycle 2.23 At the median fol-
low-up of 5 years, the progression-free survival rate was
84%, although outcomes were excellent only for those
with GCB subtype lymphoma (95% for GCB vs. 44% for
non-GCB subtype).23 Only about one-third of patients in
our trial had information regarding GCB or non-GCB sub-
type, and outcomes were similar irrespective of subtype.
Future studies evaluating risk-adapted therapy may need
to integrate histological subtyping, be limited to the GCB
Risk-adapted R-EPOCH in DLBCL
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Table 1. Characteristics of the entire population and complete responders strat-
ified by number of EPOCH treatment cycles. 
                                                             Entire                 CR                     CR
                                                          population        ≤4 cycles         5-6 cycles
N. treated                                                          106                        24                          40
Male gender, n (%)                                   91 (86%)            19 (79%)              37 (93%)
Median age, years                                            44                       43.5                         44
CD4 cell count
Median                                                       191/mL                237/mL                230.5/mL
N (%) of patients with ≤100/ L           33 (31%)              5 (21%)               12 (30%)
Concurrent antiretroviral                        75 (71%)            16 (67%)              29 (75%)
therapy, n (%)                                                     
Concurrent or sequential 
rituximab, n (%)
Concurrent                                              51 (48%)            14 (42%)              21 (53%)
Sequential                                               56 (52%)            10 (58%)              19 (47%)
Local histology, n (%)*
Diffuse large cell                                   78 (74%)            17 (71%)              28 (70%)
High grade                                              25 (33%)              7 (29%)               12 (30%)
Bone marrow involvement 
at diagnosis, n (%)                                    15 (14%)              5 (21%)                 3 (8%)
Stage III-IV, n (%)                                      84 (79%)            17 (71%)              30 (75%)
Elevated LDH, n (%)                                 72 (68%)            15 (63%)              28 (70%)
ECOG PS 2, n (%)                                      25 (24%)              3 (13%)               10 (25%)
Age-adjusted IPI risk factors, n (%)
0                                                                   8 (8%)                      0                      5 (12%)
1                                                                 28 (26%)            12 (50%)               8 (20%)
2                                                                 51 (48%)            10 (40%)              19 (48%)
3                                                                19 (18%)              2 (10%)                8 (20%)
* pathology as determined by local pathologist. CR: complete response; LDH: lactate dehydroge-
nase; ECOG PS: Eastern Cooperative Oncology Group Performance Status; IPI: International
Prognostic Index.
Table 2. Clinical outcomes for entire population and complete responders strat-
ified by number of EPOCH treatment cycles. 
                                                 Entire                        CR                          CR
                                             population               ≤4 cycles               5-6 cycles
Number                                             106                                 24                                 40
Median follow-up                      30 months                 36.5 months                40 months
(range)                                           (0-68)                          (1-67)                          (5-66)
N. relapsed after CR               10/64  (16%)                 4/24 (17%)                 6/40 (15%)
                                                (95% CI: 8%- 27%)     (95% CI 5%-37%)     (95% CI 6%-30%)
EFS rate, % (95% CI)                                                                                                     
At 1 year                             71% (61%-79%)         91% (69%-98%)         90% (76%-96%)
At 2 years                            64% (54%-73%)         78% (55%-90%)         85% (70%-93%)
Time to progression, 
% (95% CI)                                                                                                                       
At 1 year                              77% (67%-84%)         91% (69%-98%)         92% (78%-97%)
At 2 years                            73% (63%-81%)         91% (69%-98%)         87% (72%-94%)
OS rate, % (95% CI)                                                                                                       
At 1 year                              78% (68%-85%)         91% (69%- 98%)        95% (81%-99%)
At 2 years                            68% (58%-76%)         78% (55%-90%)         90% (75%-96%)
CR: complete response; 95% CI. 95% confidence interval; EFS: event-free survival, OS: overall sur-
vival.
lymphoma subtype and consider other molecular charac-
teristics that have prognostic relevance.24
Interim restaging is recommended to identify patients
whose disease has not responded well to, or has pro-
gressed, on induction therapy after two to four cycles of
therapy.2 Staging is recommended using FDG-PET inte-
grated with CT (FDG-PET/CT) at diagnosis, after two to
four cycles of therapy, and at the end of treatment.2 A
negative PET scan after two to four cycles of induction
therapy has been associated with significantly higher
event-free survival and overall survival rates in some
studies,25-28 but not others.29-32 Although several studies
failed to show improvement in clinical outcomes when
therapy was tailored to FDG-PET/CT response,33,34 these
studies were designed to evaluate more aggressive thera-
py in patients with persistent FDG-avid lesions, not de-
escalation of therapy in patients who had an early FDG
response. Differentiation of reactive adenopathy from
active lymphoma may be challenging in patients with
HIV-associated lymphoma, although this may be less
problematic in patients with well-controlled viremia.35
Although preliminary results reported by Dunleavy et al.23
regarding use of interim FDG-PET/CT as a pharmacody-
namic biomarker for tailoring de-escalation appears
promising in HIV-associated lymphoma, further study is
required in multicenter prospective clinical trials.
Our analysis has several strengths and limitations. The
strengths include the prospective nature of the trial, and
the protocol-specified guidelines for treatment duration
based on radiographic response. The limitations include
the post-hoc analysis examining response durability
based on rapidity of response and number of treatment
cycles, and the fact that the observations were not based
on an adequately powered comparison between the stan-
dard approach of six treatment cycles compared with a
risk-adapted approach. Nevertheless, given recent evi-
dence that four cycles of R-CHOP constitute adequate
therapy for a low-risk population,4 the findings of our
study indicating the feasibility of a response-adapted de-
escalation strategy in a higher-risk population with HIV-
associated lymphoma, and the clinical utility of interim
FDG/PET, there is now a compelling rationale to prospec-
tively evaluate the use of interim FDG-PET/CT after two
cycles of therapy, rather than CT as used in our trial, in
order to assess response to guide treatment duration in
patients with HIV-associated lymphoma.
Disclosures
No conflicts of interest to disclose.
Contributions
The manuscript was written by JAS and was approved by all
co-authors. The clinical protocol was written by JAS, JYL, and
LDK. The data and statistical analyses were performed by JYL
and administrative support and oversight were provided by
RM. Pathological review of tumor specimens was performed by
EC and AC. Individuals who contributed subjects to the trial
included JAS, LDK, JCR, RFA, DA, AN, DHH, LR, EC, WW,
and AC. 
Acknowledgments
This study was coordinated by the AIDS Malignancy Consortium
(Ronald Mitsuyasu, MD, Chair). 
Funding 
This study was supported in part by Public Health Service
grant n. UM1CA121947, the National Cancer Institute,
National Institutes of Health, and the Department of Health and
Human Services.
J.A. Sparano et al.
734 haematologica | 2021; 106(3)
Figure 2. Kaplan-Meier estimates of outcomes in patients achieving complete response to response-adapted EPOCH chemotherapy, stratified by number of treat-
ment cycles. (A-C) Patients are stratified into two groups: a group that received four or fewer cycles of EPOCH chemotherapy and a group that received five or six
cycles. Estimates are shown for event-free survival (A), time to progression (B) and overall survival (C).
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